We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 7.8000.0%Oct 27 12:00 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (3826)10/16/2014 11:02:37 AM
From: richardred  Read Replies (1) of 6089
ARTW-From a 52 week high yesterday back to trading just above a 52 low. The company just reporting .14 cents in the last qtr. and a increased backlog. Traders can manipulate this company all they want. I added shares today because at 5.30. they IMO are trading on fundamentals again. I haven't sold a single share of my re-entry yet, and added shares today. I can outlast day traders. FWIW- I could be wrong, but I now believe AS could be a game changer for the company.

Company PR snip-Our agricultural sales are strong, and we've seen an increase in backlog over last year in every segment. Our products serving the livestock and dairy sectors have been very strong and are providing the counter-cyclical strength and stability we seek during times of weak row-crop commodity prices."

IF this AS contract was announced for Swine Behavioral. IMO any potential orders related for Ebola could have a material impact.

>Art's-Way announces two medical research contracts
Art's Way announces that Art's Way Scientific was awarded a sole source contract for a "High Output Swine Behavioral Unit" for the University of Illinois Department of Agricultural Nutritional Sciences Division. The testing unit, valued at $620,000, will support Dr. Ryan Dilgers work to study the nutritional effects of infant formula in brain development. Art's Way Scientific recently signed contracts for an additional $290,000 in business, including a swine research unit for Recombinetics, a company that develops genetic lines of swine bred to duplicate human diseases like heart disease, diabetes and cancer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext